openPR Logo
Press release

Rheumatoid Arthritis Market Expected to Experience Major Growth by 2034, According to DelveInsight | AbbVie, Pfizer, Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH

10-01-2024 11:03 PM CET | Health & Medicine

Press release from: DelveIinsight Business Research

Rheumatoid Arthritis Market Expected to Experience Major

The Rheumatoid Arthritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Rheumatoid Arthritis pipeline products will significantly revolutionize the Rheumatoid Arthritis market dynamics.

DelveInsight's "Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Rheumatoid Arthritis, historical and forecasted epidemiology as well as the Rheumatoid Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Rheumatoid Arthritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Rheumatoid Arthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Rheumatoid Arthritis Market Insight
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Rheumatoid Arthritis Market Report:
• The Rheumatoid Arthritis market size was valued approximately USD 29 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In January 2024, Rise Therapeutics disclosed the enrollment of its initial participant in the Phase I clinical study of R-2487 for individuals diagnosed with rheumatoid arthritis.
• In December 2023, MyMD Pharmaceuticals declared that the Investigational New Drug (IND) application for a Phase II clinical trial of oral MYMD-1 for rheumatoid arthritis treatment has received clearance from the US FDA. The company is currently preparing to commence the trial in the first quarter of 2024.
• Rabeximod has the potential to become a viable treatment option in the rheumatoid arthritis market, as it directly targets a clinical gap by offering beneficial tolerability, a unique mechanism of action, and accessibility for both early and late stages of the disease.
• As per the World Health Organization (2023), approximately 70% of individuals affected by rheumatoid arthritis are female, and 55% are aged 55 years or older.
• The collective number of diagnosed prevalent cases of rheumatoid arthritis in the 7MM was estimated to be approximately 4,200,000 in 2023 and is anticipated to rise throughout the study duration.
• In 2023, the United States reported the highest number of prevalent rheumatoid arthritis cases among the 7MM, with approximately 1,430,000 diagnoses. Additionally, this number is projected to rise throughout the forecast period.
• In 2023, the age bracket of 55-64 years accounted for the highest number of cases, approximately 450,000, followed by the age group of 65 years and above in the United States.
• Key Rheumatoid Arthritis Companies: Eli Lilly and Company/Incyte Corporation, AbbVie, Cyxone, IGM Biosciences, Regeneron/Sanofi, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others
• Key Rheumatoid Arthritis Therapies: OLUMIANT (barticinib), RINVOQ (upadacitinib), Rabeximod (Rob 803), Imvotamab, Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others
• The Rheumatoid Arthritis epidemiology based on gender analyzed that according to Pediatric Rheumatology prevalence rate is consistently higher in girls in comparison to boys

Rheumatoid Arthritis Overview
Rheumatoid Arthritis (JIA), also known as juvenile rheumatoid arthritis (JRA), is the most common form of arthritis in children under the age of 16. It is a chronic autoimmune disease characterized by inflammation in the joints, which leads to pain, stiffness, swelling, and sometimes loss of joint function.

Get a Free sample for the Rheumatoid Arthritis Market Report:
https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Rheumatoid Arthritis Market
The dynamics of the Rheumatoid Arthritis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
Rheumatoid Arthritis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Rheumatoid Arthritis Epidemiology Segmentation:
The Rheumatoid Arthritis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Rheumatoid Arthritis
• Prevalent Cases of Rheumatoid Arthritis by severity
• Gender-specific Prevalence of Rheumatoid Arthritis
• Diagnosed Cases of Episodic and Chronic Rheumatoid Arthritis
Download the report to understand which factors are driving Rheumatoid Arthritis epidemiology trends @ Rheumatoid Arthritis Epidemiological Insights
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Rheumatoid Arthritis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Rheumatoid Arthritis market or expected to get launched during the study period. The analysis covers Rheumatoid Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Rheumatoid Arthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Rheumatoid Arthritis Therapies and Key Companies
• OLUMIANT (barticinib): Eli Lilly and Company/Incyte Corporation
• RINVOQ (upadacitinib): AbbVie
• Rabeximod (Rob 803): Cyxone
• Imvotamab: IGM Biosciences
• Sarilumab (Kevzara): Regeneron/Sanofi
• Baricitinib: Eli Lilly and Company
• Certolizumab pegol: UCB BIOSCIENCES GmbH
• Upadacitinib: AbbVie
• Tofacitinib: Pfizer
• Sarilumab SAR153191 (REGN88): Sanofi
• GenaKumab: Changchun GeneScience Pharma
• AIN457: Novartis
• Etanercept: Istituto Giannina Gaslini

To know more about Rheumatoid Arthritis treatment, visit @ Rheumatoid Arthritis Medications
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Rheumatoid Arthritis Market Drivers
• Important progress has been made regarding understanding disease pathology, diagnosis, and treatment effects in Rheumatoid Arthritis
• Population rates of social anxiety disorder in children and young people have been investigated in several countries
• Many therapies are under investigation in various phases of clinical trials

Rheumatoid Arthritis Market Unmet Needs
• Challenge in recognition of condition
• Development of novel therapies
• Limited availability in services
• Poor disease understanding
• Development of effective treatment

Scope of the Rheumatoid Arthritis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Rheumatoid Arthritis Companies: Eli Lilly and Company/Incyte Corporation, AbbVie, Cyxone, IGM Biosciences, Regeneron/Sanofi, UCB BIOSCIENCES GmbH, AbbVie, Pfizer, Changchun GeneScience Pharma, Novartis, Istituto Giannina Gaslini, and others
• Key Rheumatoid Arthritis Therapies: OLUMIANT (barticinib), RINVOQ (upadacitinib), Rabeximod (Rob 803), Imvotamab, Sarilumab (Kevzara), Baricitinib, Certolizumab pegol, Upadacitinib, Tofacitinib, Sarilumab SAR153191 (REGN88), GenaKumab, AIN457, Etanercept, and others
• Rheumatoid Arthritis Therapeutic Assessment: Rheumatoid Arthritis current marketed and Rheumatoid Arthritis emerging therapies
• Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and Rheumatoid Arthritis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Rheumatoid Arthritis Unmet Needs, KOL's views, Analyst's views, Rheumatoid Arthritis Market Access and Reimbursement

Discover more about therapies set to grab major Rheumatoid Arthritis market share @ Rheumatoid Arthritis market forecast
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Rheumatoid Arthritis Market Report Introduction
2. Executive Summary for Rheumatoid Arthritis
3. SWOT analysis of Rheumatoid Arthritis
4. Rheumatoid Arthritis Patient Share (%) Overview at a Glance
5. Rheumatoid Arthritis Market Overview at a Glance
6. Rheumatoid Arthritis Disease Background and Overview
7. Rheumatoid Arthritis Epidemiology and Patient Population
8. Country-Specific Patient Population of Rheumatoid Arthritis
9. Rheumatoid Arthritis Current Treatment and Medical Practices
10. Rheumatoid Arthritis Unmet Needs
11. Rheumatoid Arthritis Emerging Therapies
12. Rheumatoid Arthritis Market Outlook
13. Country-Wise Rheumatoid Arthritis Market Analysis (2020-2034)
14. Rheumatoid Arthritis Market Access and Reimbursement of Therapies
15. Rheumatoid Arthritis Market Drivers
16. Rheumatoid Arthritis Market Barriers
17. Rheumatoid Arthritis Appendix
18. Rheumatoid Arthritis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Rheumatoid Arthritis Pipeline https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Rheumatoid Arthritis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Rheumatoid Arthritis market. A detailed picture of the Rheumatoid Arthritis pipeline landscape is provided, which includes the disease overview and Rheumatoid Arthritis treatment guidelines.

Rheumatoid Arthritis Epidemiology https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Rheumatoid Arthritis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Rheumatoid Arthritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Cart-related Neurotoxicity Market https://www.delveinsight.com/report-store/cart-related-neurotoxicity-nt-market
DelveInsight's "CART-related Neurotoxicity Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the CART-related Neurotoxicity, historical and forecasted epidemiology as well as the CART-related Neurotoxicity market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Crows Feet Market
https://www.delveinsight.com/report-store/crows-feet-market
DelveInsight's "Crows Feet Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Crows Feet, historical and forecasted epidemiology as well as the Crows Feet market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Herpes Simplex Virus Market
https://www.delveinsight.com/report-store/herpes-simplex-market
DelveInsight's "Herpes Simplex Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Listeriosis Market
https://www.delveinsight.com/report-store/listeriosis-market
DelveInsight's comprehensive report titled "Listeriosis Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of Listeriosis. The report presents historical and projected epidemiological data covering incident cases of listeriosis, age-specific cases of listeriosis, gender-specific cases of listeriosis, risk-associated cases of listeriosis, and treated cases of listeriosis.

Point Of Care Glucose Testing Market https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Substance Drug Abuse Market https://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance (Drug) Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rheumatoid Arthritis Market Expected to Experience Major Growth by 2034, According to DelveInsight | AbbVie, Pfizer, Regeneron/Sanofi, Eli Lilly and Company, UCB BIOSCIENCES GmbH here

News-ID: 3675015 • Views:

More Releases from DelveIinsight Business Research

Sickle Cell Disease Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA, CRISPR Therapeutics, Vertex Pharmaceuticals
Sickle Cell Disease Market Forecasted to Surge in Coming Years, 2024-2034 Analys …
DelveInsight's "Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom. To Know in detail about the Sickle Cell Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sickle Cell Disease Market Forecast https://www.delveinsight.com/sample-request/sickle-cell-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Opioid Use Disorder Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Braeburn Pharmaceuticals, BioXcel Therapeutics, Braeburn Pharmaceuticals, Alkermes, Inc., Indivior Inc.
Opioid Use Disorder Market to Show Remarkable Growth Trends from 2024 to 2034, D …
The Opioid Use Disorder market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Opioid Use Disorder pipeline products will significantly revolutionize the Opioid Use Disorder market dynamics. DelveInsight's "Opioid Use Disorder Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Opioid Use Disorder, historical and forecasted epidemiology as well as the Opioid Use
Obesity Market on Track for Major Expansion by 2034, According to DelveInsight | Rhythm Pharmaceuticals, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharm
Obesity Market on Track for Major Expansion by 2034, According to DelveInsight | …
DelveInsight's "Obesity Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Obesity, historical and forecasted epidemiology as well as the Obesity market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Obesity market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Obesity Market Forecast https://www.delveinsight.com/sample-request/weight-loss-weight-management-obesity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key facts of the Obesity Market
Necrotizing Enterocolitis Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Infant Bacterial Therapeutics, Noveome Biotherapeutics, Siolta Therapeutics, The Emmes Company
Necrotizing Enterocolitis Market Growth to Accelerate in Forecast Period (2024-2 …
DelveInsight's "Necrotizing Enterocolitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Necrotizing Enterocolitis, historical and forecasted epidemiology as well as the Necrotizing Enterocolitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Necrotizing Enterocolitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Necrotizing Enterocolitis Market Forecast https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the

All 5 Releases


More Releases for Rheumatoid

How To Cure Rheumatoid Arthritis 2021 ?
Grocare® launches new kit to manage Rheumatoid Arthritis - New findings support research-based kit for management of Rheumatoid Arthritis Pune, May 13, 2021: Pune-based Grocare® has recently launched an advanced research-based kit that alleviates and controls Rheumatoid Arthritis, conditions. This kit contains Absogen®, GC® and Acidim® designed to correct mitochondrial imbalance, build immunity and balance PH, respectively. Grocare® is a pharmaceutical company that has conducted extensive research on Rheumatoid Arthritis. The company’s data
Major Advancements| Competitor Landscape: Rheumatoid Arthritis
Researchmoz added Most up-to-date research on "Competitor Landscape: Rheumatoid Arthritis" to its huge collection of research reports. Competitor Landscape: Rheumatoid Arthritis Summary Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the Rheumatoid Arthritis (RA) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher - - Executive Summary: Contains analysis of key market events that have occurred during
Global Rheumatoid Arthritis Drugs Market | MarketResearchReports.biz
Latest industry research report on: Global Rheumatoid Arthritis Drugs Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts The Rheumatoid Arthritis Drugs Market has been comprehensively detailed in the report with special focus on a range of key elements such as market share, forecast and base figures, CAGR, driving factors, growth restraints, and business opportunities. Buyers of the report are expected to be informed about significant
Rheumatoid Arthritis Drug Market Rheumatoid Arthritis Clinical Pipeline Report 2 …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Antirheumatoids: Call of Rheumatoid Arthritis 1.1 Prologue towards Rheumatoid Arthritis 1.2 Obtainable Treatment for Rheumatoid Arthritis Molecular Mechanism of Antirheumatoids 2.1 Purpose of DMARDs in Rheumatoid Arthritis 2.2 Role of Biological Agents in Rheumatoid Arthritis 2.2.1 TNF- Inhibitors 2.2.2 Interleukin -1 and IL-6 Blockers Classification of Rheumatoid Arthritis Drugs 3.1
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the